Why India has restricted chlorpheniramine, phenylephrine medicines for children under 4 | Explained
The Indian government has mandated that all fixed-dose combination medicines containing chlorpheniramine and phenylephrine must carry a warning label against use in children under four. This decision follows expert advice regarding the vulnerability of young children to adverse medication effects.
Why it matters
Informs parents and caregivers about significant changes in pediatric medication safety regulations.
The story so far: The Union Health Ministry this past week tightened controls on all fixed-dose combinations (FDCs) containing chlorpheniramine maleate and phenylephrine hydrochloride , requiring manufacturers to carry a clear warning that they must not be used in children below four years of age.
Chlorpheniramine is an antihistamine. It can reduce allergy symptoms such as a runny nose and sneezing. Phenylephrine is a decongestant, intended to relieve a blocked nose.
An FDC puts both ingredients into one medicine. Such combinations are commonly encountered in cold/allergy preparations.
The government’s action does not mean every medicine containing either ingredient individually has been banned. The specific regulatory action concerns FDCs containing the two ingredients together.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in